A Phase 3 interventional study of Travoprost and Placebo Vehicle in Open Angle Glaucoma and Ocular Hypertension, sponsored by Ocular Therapeutix, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 5th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2016, is one of 16 in phase 3, and was the 40th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 565 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension
This was a prospective, multicenter, randomized, parallel-arm, double masked, placebo vehicle (PV) controlled study conducted to evaluate the safety and IOP-lowering efficacy of OTX-TP, a sustained release drug product placed in the canaliculus of the eyelid in subjects with open-angle glaucoma or ocular hypertension. A total of up to 550 subjects (1100 eyes) with a clinical diagnosis of open-angle glaucoma or ocular hypertension in both eyes received either OTX-TP or PV to evaluate the safety and efficacy of OTX-TP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OTX-TP (sustained release travoprost) Intracanalicular Depot
Drug: Travoprost
PV (Placebo Vehicle) Intracanalicular Depot
Other: Placebo Vehicle
Mean IOP
Time frame: Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit
Mean IOP
Time frame: Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit
Mean IOP
Time frame: Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit
Number of Participants With Serious Adverse Events
Number of Participants with Serious Adverse Events
Time frame: Through study completion, an average of 23 months
| Milestone | OTX-TP | Placebo Vehicle (PV) |
|---|---|---|
| Started | 348 | 217 |
| Completed | 343 | 211 |
| Not completed | 5 | 6 |
| mmHg | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) |
|---|---|---|
| 8AM | 21 ± 0.2 | 22.9 ± 0.2 |
| 10AM | 20.2 ± 0.2 | 21.9 ± 0.2 |
| 4PM | 19.5 ± 0.2 | 21.5 ± 0.2 |
| mmHg | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) |
|---|---|---|
| 8AM | 21.9 ± 0.2 | 26.9 ± 0.3 |
| 10AM | 25.1 ± 0.2 | 25 ± 0.2 |
| 4PM | 24.8 ± 0.2 | 24.6 ± 0.2 |
| mmHg | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) |
|---|---|---|
| 8AM | 22.8 ± 0.2 | 23.2 ± 0.3 |
| 10AM | 21.7 ± 0.2 | 22.5 ± 0.2 |
| 4PM | 21.4 ± 0.2 | 22.1 ± 0.2 |
Number of Participants with Serious Adverse Events
| Participants | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) |
|---|---|---|
| Number of Participants With Serious Adverse Events | 7 | 6 |
Collected over through study duration, an average of 23 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | 1/348 (0.3%) | 7/348 (2%) | 132/348 (37.9%) |
| Placebo Vehicle (PV) | 0/217 (0%) | 6/217 (2.8%) | 65/217 (30%) |
| Event | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) |
|---|---|---|
| Serious Adverse EventInfections and infestations | 1/348 | 2/217 |
| Serious Adverse EventNervous system disorders | 2/348 | 0/217 |
| Serious Adverse EventCardiac disorders | 1/348 | 1/217 |
| Serious Adverse EventRespiratory, thoracic and mediastinal disorders | 0/348 | 1/217 |
| Serious Adverse EventsEar and labyrinth disorders | 0/348 | 1/217 |
| Serious Adverse EventInjury, poisoning and procedural complications | 0/348 | 1/217 |
| Serious Adverse EventNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/348 | 0/217 |
| Serious Adverse EventVascular disorders | 1/348 | 0/217 |
| Serious Adverse EventSkin and subcutaneous tissue disorders | 1/348 | 0/217 |
| Event | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) |
|---|---|---|
| Adverse EventGeneral disorders | 132/348 | 65/217 |
| Age, Categorical(Participants) | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 160 | 91 | 251 |
| >=65 years | 188 | 126 | 314 |
| Age, Continuous(years) | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) | Total |
|---|---|---|---|
| Mean | 65 ± 11 | 65 ± 11 | 65 ± 11 |
| Sex: Female, Male(Participants) | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) | Total |
|---|---|---|---|
| Female | 185 | 135 | 320 |
| Male | 163 | 82 | 245 |
| Race/Ethnicity, Customized(Participants) | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) | Total |
|---|---|---|---|
| Caucasian | 247 | 159 | 406 |
| African American | 84 | 48 | 132 |
| Other | 17 | 10 | 27 |
| Region of Enrollment(participants) | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Placebo Vehicle (PV) | Total |
|---|---|---|---|
| United States | 348 | 217 | 565 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Mar 2019, 28 months.
Results were first posted in Oct 2021, 2 years 6 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 28 months is close to that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost